Ruby Zhan

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised the sponsors and underwriters of BrainAurora Medical Technology, a provider of medical diagnostics and digital therapies, in connection with the company’s HK$583 million initial public offering.